Zenas Biopharma Inc

Insider buying of Zenas Biopharma’s shares signals confidence while Phase III data on obexelimab could drive new drug approval and a stock rebound.

Fairmount Funds Management buys 150,000 Zenas Biopharma shares at $20, backing Phase IIa obexelimab, fast‑track status, and insider confidence for future psoriasis therapy.

CEO insider buying at Zenas Biopharma shows strong confidence amid market volatility—discover how recent purchases may signal future upside.

Insider buying surge at Zenas Biopharma shows modest yet consistent confidence, tied to a 21% weekly gain, analyst upgrades and strong social‑media buzz—watch the pipeline for upside.

Insider buying surges at Zenas Biopharma, boosting confidence in its immunology pipeline and potential pricing strategy – see how this could shape investors’ next move.

CEO insider buying fuels optimism for Zenas Biopharma’s volatile stock – a calculated 100k‑share spree that signals confidence amid clinical‑trial uncertainty.